---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-039248"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:32:33.793907+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics extends cash runway into 2027; will require partner for zerlasiran Phase 3

## Summary
- Net loss of $45.3M ($0.33 per share) for FY2024, compared to $54.2M loss in FY2023.
- Cash, cash equivalents and short-term investments of $147.3M at Dec 31, 2024.
- Collaboration revenue $43.1M (up $12.2M YoY); R&D expenses $67.9M (up $11M).
- Zerlasiran Phase 3 CVOT will not start without a partner; cash guidance extended into 2027.
- Divesiran Phase 2 PV enrollment expected to complete by end-2025; Hansoh Pharma exited collaboration.

## SEC filing metadata
- accession: 0001193125-25-039248
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525039248/0001193125-25-039248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525039248/d925669d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-039248
- JSON: https://secwatch.observer/filing/0001193125-25-039248.json
- Plain text: https://secwatch.observer/filing/0001193125-25-039248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.